SMAD1 and familial pancreatic carcinoma: A recent study demonstrated that treatment with a TRC105 antibody, which inhibits the interaction of BMP9 with ENG, on CAFs could not suppress tumor growth in a syngeneic murine model of pancreatic cancer [62], indicating ENG‐mediated BMP–Smad1/5 signaling has little tumor‐promoting ability.